Company Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.
The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders.
Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
| Country | United States |
| IPO Date | Jun 1, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 912 |
| CEO | William H. Lewis J.D., M.B.A. |
Contact Details
Address: 700 US Highway 202/206 Bridgewater, New Jersey United States | |
| Website | https://www.insmed.com |
Stock Details
| Ticker Symbol | INSM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001104506 |
| CUSIP Number | 457669307 |
| ISIN Number | US4576693075 |
| Employer ID | 54-1972729 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William H. Lewis J.D., M.B.A. | President, Chief Executive Officer & Chairman |
| Michael Alexander Smith J.D. | Chief Legal Officer & Corporate Secretary |
| Roger Adsett M.B.A. | Chief Operating Officer |
| Sara M. Bonstein M.B.A. | Chief Financial Officer |
| Brian K. Kaspar Ph.D. | Chief Scientific Officer |
| Dr. Martina Flammer M.B.A., M.D. | Chief Medical Officer |
| Eleanor Barisser | Associate Director of Investor Relations |
| John Drayton Wise M.B.A. | Chief Commercial Officer |
| Mandy Fahey | Executive Director of Corporate Communications |
| S. Nicole Schaeffer M.B.A. | Chief People Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Sep 16, 2024 | 4 | Filing |
| Sep 16, 2024 | 4 | Filing |
| Sep 10, 2024 | 4 | Filing |
| Sep 10, 2024 | 4 | Filing |
| Sep 03, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 03, 2024 | 4 | Filing |